Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis

Table 1 Baseline characteristics evaluation of all participants

Variables	Total	Control	PUFA	P value
n	78	39	39
Age (yr)	51.9 ± 7.8	50.4 ± 7.2	52.6 ± 6.6	0.306
Male, n (%)	70 (89.7)	36 (92.3)	34 (87.2)	0.178
BMI (kg/m2)	27.9 ± 1.6	27.2 ± 1.3	28.0 ± 1.4	0.225
Smoking, n (%)	45 (57.7)	22 (56.4)	23 (59.0)	0.154
Family history, n (%)	3 (3.8)	1 (2.6)	2 (5.1)	0.237
ALT (U/L)	89.9 ± 10.4	91.3 ± 10.2	89.2 ± 12.4	0.313
AST (U/L)	82.4 ± 11.6	83.5 ± 8.9	82.0 ± 9.6	0.196
Bilirubin, total (md/dL)	1.2 ± 0.3	1.2 ± 0.2	1.2 ± 0.4	0.354
Bilirubin, direct (md/dL)	0.8 ± 0.2	0.7 ± 0.3	0.8 ± 0.4	0.366
FBG (mmol/L)	6.1 ± 0.3	6.1 ± 0.2	6.1 ± 0.5	0.117
TG (mmol/L)	2.6 ± 0.4	2.6 ± 0.3	2.5 ± 0.3	0.252
TC (mmol/L)	5.6 ± 0.7	5.5 ± 0.3	5.6 ± 0.4	0.408
LDL-C (mmol/L)	3.9 ± 0.7	3.9 ± 0.4	3.9 ± 0.3	0.387
HDL-C (mmol/L)	1.1 ± 0.2	1.1 ± 0.1	1.1 ± 0.2	0.163
CRP (mg/L)	10.4 ± 1.3	10.6 ± 1.1	10.0 ± 1.5	0.204
MDA (nmol/mL)	0.6 ± 0.1	0.6 ± 0.1	0.6 ± 0.2	0.339
Type IV collagen (ng/mL)	4.9 ± 0.5	4.8 ± 0.6	4.9 ± 0.2	0.286
P-III-P (U/mL)	0.9 ± 0.3	0.9 ± 0.1	0.9 ± 0.4	0.350
Weekly exercise time (min)	60.3 ± 7.3	61.2 ± 5.6	60.1 ± 4.6	0.313

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; PUFA: Poly-unsaturated fatty acid; MDA: Malondialdehyde; LDL-C: Lipoprotein-cholesterol; HDL-C: High-density lipoprotein-cholesterol; CRP: C-reactive protein; FBG: Fasting blood glucose; TG: Triglyceride; TC: Total cholesterol.